HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

6th Edition of World Congress on Infectious Diseases

June 24-26, 2024 | Paris, France

June 24 -26, 2024 | Paris, France
Infection 2024

Filip Razga

Speaker at Infection Conferences - Filip Razga
Selecta Biotech SE, Slovakia (Slovak Republic)
Title : Effective reduction of SARS-CoV-2 RNA levels in transfected lung cells using a tailor-made therapeutic oligonucleotide


More than four years after the outbreak of the COVID-19 pandemic, the SARS-CoV-2 virus is still causing lasting damage around the world, impacting the health and lives of many. Preventive measures, such as widespread administration of vaccines, is playing a role in reducing the severity of cases. For those who require treatment, clinicians can try to treat the disease and its symptoms with existing drugs. However, an effective therapy specifically targeted against SARS-CoV-2 is still lacking. Here, we report the antiviral potential of a tailor-made oligonucleotide-based inhibitor targeting SARS-CoV-2, called ASC1R, which showed spontaneous cellular uptake and a remarkable >94% efficacy in reducing RdRp RNA levels in transfected lung cell lines following a single application. The therapeutic potential of the structurally unique ASC1R could translate into substantial clinical benefits for patients with COVID-19, while the versatility of the platform could be exploited in the development of analogue antivirals for other viral diseases. The findings could help meet the global challenge of developing new and safe treatment modalities.


Dr. Razga has more than 20 years of professional experience in oncology with a focus on biotechnology within the last decade. He is trained in Physical and Biomolecular chemistry and has a primary research interest in RNA structure and function. He is currently leveraging his expertise in the development of new therapeutic modalities using the antisense platform to develop quality healthcare products that have the potential to redefine treatment outcomes. He is the author of more than 60 scientific papers and developed several proprietary technologies aiming at precise diagnosis and personalized therapeutic approaches.